These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 33927375)

  • 1. Metabolic barriers to cancer immunotherapy.
    DePeaux K; Delgoffe GM
    Nat Rev Immunol; 2021 Dec; 21(12):785-797. PubMed ID: 33927375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
    Uche IK; Kousoulas KG; Rider PJF
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity.
    Zhang S; Zhang X; Yang H; Liang T; Bai X
    Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189022. PubMed ID: 37993001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Going viral with cancer immunotherapy.
    Lichty BD; Breitbach CJ; Stojdl DF; Bell JC
    Nat Rev Cancer; 2014 Aug; 14(8):559-67. PubMed ID: 24990523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition.
    Santos JM; Havunen R; Hemminki A
    Methods Enzymol; 2020; 635():205-230. PubMed ID: 32122546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
    Oh CM; Chon HJ; Kim C
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
    Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
    Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
    Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
    Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
    Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
    Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.
    Liu X; Zhao Y; Wu X; Liu Z; Liu X
    Front Oncol; 2022; 12():931104. PubMed ID: 35924168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination cancer immunotherapies tailored to the tumour microenvironment.
    Smyth MJ; Ngiow SF; Ribas A; Teng MW
    Nat Rev Clin Oncol; 2016 Mar; 13(3):143-58. PubMed ID: 26598942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
    Muscolini M; Tassone E; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy.
    Fu Z; Mowday AM; Smaill JB; Hermans IF; Patterson AV
    Cells; 2021 Apr; 10(5):. PubMed ID: 33923305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
    Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
    Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.